YolTech Therapeutics

Dosing Underway in World’s First in Vivo CRISPR...
CMN Clinical

Aug. 28, 2024

YolTech Therapeutics announced last week that the first two patients have been dosed in a Phase 1 trial of YOLT-203, an in vivo CRISPR-based...

YolTech Therapeutics

Type 1 Primary Hyperoxaluria, PH1, (NCT06511349)
Sponsors:
RenJi Hospital
Indicator
IND Enabling
Phase I
Phase II
Phase III
Transthyretin Amyloidosis, ATTR, (NCT06539208)
Sponsors:
YolTech Therapeutics Co., Ltd
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Familial Hypercholesterolemia, FH, (NCT06461702)
Sponsors:
YolTech Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
Transthyretin Amyloidosis Cardiomyopathy, TTR, (NCT06082050)
Sponsors:
YolTech Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine